Molecular and cellular heterogeneity: the hallmark of glioblastoma.
暂无分享,去创建一个
Eric C Leuthardt | Gavin P Dunn | Albert H Kim | E. Leuthardt | G. Dunn | David H Kim | A. Kim | Diane Aum | Thomas L. Beaumont | Diane J Aum | David H Kim | Thomas L Beaumont
[1] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[2] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[3] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[4] K. Aldape,et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.
[5] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[6] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[7] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[8] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[9] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[10] B. Rosen,et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. , 2013, The Journal of clinical investigation.
[11] Scott L. Pomeroy,et al. Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.
[12] Tatsuya Ozawa,et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.
[13] J. Stockman,et al. A Network Model of a Cooperative Genetic Landscape in Brain Tumors , 2011 .
[14] Serban Nacu,et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. , 2010, Cancer cell.
[15] Yoshitaka Narita,et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.
[16] Rebecca A Betensky,et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.
[17] Se Hoon Kim,et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.
[18] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[19] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[20] R. McLendon,et al. Integrin alpha 6 regulates glioblastoma stem cells. , 2010, Cell stem cell.
[21] J. Uhm. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .
[22] Robert J Dempsey,et al. Science Times , 2022 .
[23] Tzong-Shiue Yu,et al. A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .
[24] L. Ricci-Vitiani,et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.
[25] A. Iavarone,et al. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. , 2012, Cancer cell.
[26] J. Greenman,et al. Genetic analysis of head and neck squamous cell carcinoma using comparative genomic hybridisation identifies specific aberrations associated with laryngeal origin. , 2007, Cancer letters.
[27] J. C. Love,et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. , 2014, Cancer discovery.
[28] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[29] Debyani Chakravarty,et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.
[30] J. Barnholtz-Sloan,et al. The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.
[31] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[32] D. Cahill,et al. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. , 2013, Neurosurgical focus.
[33] David T. W. Jones,et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge , 2014, Nature Reviews Cancer.
[34] D. Troost,et al. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas , 2004, Brain Research Reviews.
[35] Simon Kasif,et al. Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells , 2014, Cell.
[36] S. Pastorino,et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells , 2011, Proceedings of the National Academy of Sciences.
[37] T. Cloughesy,et al. Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.
[38] J. Rich,et al. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. , 2011, Cell stem cell.
[39] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[40] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[41] Shawn M. Gillespie,et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.
[42] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[43] L. Morgan,et al. The epidemiology of glioma in adults: a "state of the science" review. , 2015, Neuro-oncology.
[44] K. Aldape,et al. A multigene predictor of outcome in glioblastoma. , 2010, Neuro-oncology.
[45] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[46] Zhaoshi Jiang,et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] W. Cavenee,et al. Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma , 2006, Brain Tumor Pathology.
[48] Rong Wang,et al. Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.
[49] H. Fine,et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.
[50] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[51] C. Brennan. Genomic Profiles of Glioma , 2011, Current neurology and neuroscience reports.
[52] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[53] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[54] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[55] Lynda Chin,et al. Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.
[56] A. Krešo,et al. Evolution of the cancer stem cell model. , 2014, Cell stem cell.
[57] Jim McDermott,et al. Harnessing our opportunity to make primary care sustainable. , 2011, The New England journal of medicine.
[58] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[59] Howard A. Fine,et al. Integration and analysis of genome-scale data from gliomas , 2011, Nature Reviews Neurology.
[60] G. Reifenberger,et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas , 2010, Acta Neuropathologica.
[61] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[62] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.
[63] S. Scherer,et al. Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.
[64] R. Verhaak,et al. Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.
[65] Joseph G Boyer,et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG. , 2011, Biochemistry.
[66] Webster K. Cavenee,et al. Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development , 2008, Cancer cell.
[67] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[68] C. Brennan,et al. Molecular subclassification of diffuse gliomas: Seeing order in the chaos , 2011, Glia.
[69] R. McLendon,et al. Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.
[70] R. Klose,et al. The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.
[71] Michael R Stratton,et al. Genomics and the continuum of cancer care. , 2011, The New England journal of medicine.
[72] J. Uhm. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .
[73] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.